MEDICINAL SILVER SOLUTIONS

Silver Solutions History

Medicinal silver solutions were developed circa 1891. Widespread use of
these products by practitioners as oral and injectable antibacterials
occurred prior to 1930. There were many names for these silver products and
solutions produced by different manufacturers and pharmaceutical companies.
Some names were: Argenti Acetas, Albargin, Argonin, Argyn, Argyrol, Largin,
Lunosol, Novargan, Proganol, and Silvol, to name just a few. The
effectiveness of the silver solution, as antibacterials depended on the
standard of manufacture and the time elapsed since manufacture. In general,
the silver solutions formulated by physicians from the commercially prepared
powders were effective in varying degrees for up to 14 days from the date of
formulation. Depending upon the manufacturing process, skin staining could
occur when the products were used topically. Although chlorinated soda could
remove some of the stains, some stains remained permanent. None of these
products were as effective against bacteria as silver nitrate. However
silver nitrate had potential serious if not fatal, side effects due to its
toxicity. The silver solutions which had the highest efficacy were the
preparations made in the doctors office and which were administered
immediately, either orally or via injection.

The pharmaceutical companies continued to produce colloidal silver products,
but their use gradually fell into disfavor with the development of sulfa
drugs, and the later development of penicillin. By the mid 1970's, all of
the major U.S. pharmaceutical companies ceased production of these products.

By 1990 there were only a few people making silver solutions - mostly
dietary supplement producers. They made the product themselves, on a small
scale in the way the solutions had previously been made. Unfortunately, this
usually resulted in a totally unstable product that showed only sporadic
effectiveness. In 1992, a U.S. Doctor, was using a colloidal silver made by
a company named Silverado. He noticed that Silverado's product produced
limited effectiveness against some infections some of the time, but wasn't
effective at all against the same infection at other times. The Doctor had
the foresight to believe that silver solutions had the potential to be very
effective in treating infections if manufactured properly. He then contacted
the research department of a national pharmaceutical company, and requested
that they look into a possible problem with the Silverado product, or
research the possibility of manufacturing a better silver solution.*

This U.S. pharmaceutical company's research department found the problem
immediately with the Silverado product, and contacted the company. Silverado
stated they would work in correcting the problem.*

A few months later, the pharmaceutical company's research department
discovered a unique way to infuse the silver into one particular protein.
This produced an extremely stable mild silver protein (MSP) with enhanced
antibacterial properties. Further testing confirmed the compound to be
extremely stable. The product was then sent out to doctors, the NIH, and
universities for testing.*
Booklet Page #5
News traveled rapidly from the doctors using this newly developed MSP, as it
was effectively treating many antibiotic-resistant strains of bacteria. As a
result a number of unscrupulous individuals came out of the woodwork and
began to produce silver solutions, claiming them to be miracle drugs, based
on the results derived from this product. These substances, sold as dietary
supplements, appear to have been made the old way. They reveal little
efficacy and are inherently unstable.*

Test results of these poorly-made silver solutions reveal that many of them
contain no silver or silver ions, and are in some cases nothing more than
colored water.

Additional in vitro testing against a common bacteria (S. aureus) showed
some of these products to be totally ineffective, as noted below:

Zone of Inhibition
Source Naturals (Ultra Coloidal) 0
Silver Care 0
Kaire International 0

Although most of the newly-introduced silver solutions appeared to be
frauds, a few silver solutions tested did contain some silver, and reflected
some stability. Nevertheless, other problems were identified. For example,
although some silver solutions were stable for a few weeks, ultimately the
silver precipitated. This happened in *"all" tests conducted with solutions
of silver and water only. Some manufacturers stated that their products were
produced via electrical charge, which implied that the product contained
silver ions. Tests revealed the ion content to be no more than that of
normal tap water.Some silver products were made from silver nitrate which
can be extremely toxic if any silver nitrate remained in the product-
Additionally, protein stabilized products can have high concentrations of
nitrites, nitrates and sodium, which can be toxic. One product tested, which
was labeled as being manufactured by an FDA-approved laboratory - although
not stating a lot number or expiration date misstated the concentration of
the product by over 400 ppm. This product is called Colloidal Silver "High
Potency" by Innovative Health Products.

The Silverado product has recently tested again to see if they had corrected
their problems. A recent sample of Silverado product was tested, Lot #7328,
expiration 4/97. which revealed 4 ppm with negligible silver ions. Another
sample of the Silverado's product, Lot 16143, expiration 7/97, revealed 2
ppm with negligible silver ions. Noticeable particles were observed floating
within the sample of Silverado's product, Lot #6143.
Booklet Page #6
The new formulation was first introduced as an over-the-counter drug, and
later came out with the MSP at Low concentrations as a trace mineral dietary
supplement at 30 ppm. At concentrations above 12,000 ppm* the research lab
believes more human testing needs to be conducted before recommending this
special formulation MSP for human use.

Ongoing studies done in-vitro and in-vivo over the past three years have
revealed that these silver solutions, Special Formulation MSP (SFMSP), and
silver solution (SS) have inhibited or have been lethal against HIV. The
same effect was found in vitro regarding C. albicans., C. neoformans, the
spirochetes in Lyme disease, E. coli, S. aureus, S. pneumonia, and P.
aeruginosa. One of the lab's products also partially inhibited Enterococcus
in-vitro. Further testing at higher silver concentrations will no doubt
prove that this antibiotic-resistant strain of bacteria is also susceptible
to the lethal bactericidal effects of MSP.*

Reports from doctors and practitioners that have been using the new MSP
in-vivo for almost three years report correspondinglyin-vitro testing.

Condensed limited in-vitro testing results, limited doctors' and patients'
in-vivo reports, and toxicity studies follow. All references to MSP refer
to this new Mild Silver Protein developed and manufactured in North
America.*
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #7

Clinical Use Report Of MSP

Dr. Joseph Cardot from Colorado

Researchers have been warning the medical establishment for years that the
indiscriminate use of antibiotics could spawn, they warned, would create a
"post antibiotic world" where common, as well as uncommon, infections would
quickly escalate into fatal illnesses. The warning have been ignored; the
result is that we are - right now - facing a major threat to human life from
formerly treatable infectious conditions.

A friend of mine, Dr. Richard Callahan, York, NE, in a recent phone
conversation remarked that, in his opinion, mutated pneumoccus bacteria and
viral pneumonia will be killing thousands of Americans annually within five
years. Bad news indeed.

The good news is that Mild Silver Protein (MSP) may be an answer to the
dilemma we are facing. I have operated a family practice for 37 years where
I have treated all types of infections in patients varying in ages from
infants to over ninety.

Before prescribing any treatment I believe a doctor should determine if the
patient might suffer harmful effects from the treatment. "First Do No Harm."
The treatment should also offer the prospect of helping the patient recover.
MSP meets both of the criteria.

I started using a silver suspension in protocols for patients with
infections in January of 1992. The first patient, a female, had "walking"
viral pneumonia. She was placed on one tablespoon of the silver suspension
t.i.d. She was asymptomatic the fourth day into treatment. I was astounded.
I thought that it might have been a misdiagnosis. Since that first
experience I have treated more than 50 cases of viral pneumonia with the
same positive results. Time of treatment varies, due to patient condition
and severity of infection, from four days to thirty days. The outcome,
however, is consistently positive; the infection is cleared.

Since that first experience I have included MSP in protocols for all types
of infectious diseases with positive results.

MSP has cleared reoccurring ear infections in children who were scheduled
for tube surgery making the procedure unnecessary.
Booklet Page #8
Infectious fibromayalgia(Fibromyositis) andSjsgren's syndrome patients have
benefitted from MSP therapy; MSP therapy helps manyrheumatoid arthritis
patients with synovial fluid infections that are causing inflammation to no
longer need steroids.

SystemicCandida Albicans is successfully treated with MSP. It is so
effective we must start with small doses to controlHerxheimer effect.

Staph and other infections in the mouth(Gingivitis) have dramatically
improved with MSP therapy.

The Lyme disease spirochete(Borrelia burgdorferi) is eliminated using MSP
therapy. I have records of Lyme patients who have been taking various
antibiotics for three or more years who have become asymptomatic on MSP
therapy after just three or four weeks of treatment. The average duration to
rid the body of the spirochete is three to nine months. Systemic Candida
Albicans frequently occurs in patients with Lyme; complicating the treatment
and prolonging the duration of treatment.

Lyme disease is far more prevalent than is generally known. Lyme has been
reported in the U.S. in 43 states, and in all of Canada. I believe that
reported cases of Lyme represent only about 20% of the actual number of Lyme
cases. Lyme is routinely misdiagnosed as meningitis or as a "heat rash." A
red rash is a typical symptom of Lyme. Mild Silver Protein solutions* are
proving to be 100% effective in getting rid of the Lyme spirochete when they
are included in the treatment protocol.

The important thing about MSP therapy is that it is non-toxic. I have never
observed any side effect from using MSP therapy, and I have used it in
patients with all kinds of infections. In acute conditions as much as four
tablespoons per day has been given, with no adverse reactions observed or
reported.

HIVpositive patients have responded to MSP therapy if begun before the
advanced stages of full blown AIDS. Temple University studies indicate that
MSP kills the HIV virus in vitro. I believe that the HIV can be completely
eliminated by using higher concentrations of MSP than can be absorbed with
oral dosing. In vivo studies should be done using 250 to 750 ppm MSP
administered IV. Due to the fact that MSP is non-toxic in high
concentrations, this should prove to be a God-sent treatment for the
millions who are suffering and dying from AIDS related illnesses.

The use of AZT and other chemotherapeutic drugs, in the vain attempt to
treat AIDS is, in my view, simply death by prescription. These drugs destroy
DNA and the immune system; a case of "the cure being as bad as the disease."
Booklet Page #9
Why not use a proven to be non-toxic protocol with AIDS patients, rather
than the present approach of hitting them on the head with a hammer to get
rid of the headache?

Scientists at a major U.S. pharmaceutical company have developed a Mild
Silver Protein solvent formula (MSP). This formula, when applied to the
gums, produces dramatic improvement with the first treatment.*

Saturate a band-aid pad with MSP and apply to ringworm. The infection is
cleared in 2 to 3 days.

Psoriasis(virus in the skin) responds to MSP, applied topically. Within 3
weeks of treatment (b.i.d.) new normal skin growth is observed. It takes
three to eighteen months of MSP therapy to heal psoriasis.

MSP is so effective in treating gum diseases (Gingivitis) that, in my
opinion, if widely utilized in the population, it could eradicate gum
disease completely.

I have seen patients withsevere infections of the mouth whose symptoms
included swollen gums, tongue, and cheeks (making them unable to speak or
eat) improve immediately. Following one application of MSP most could eat.
These severe infections are completely cleared after two to four days of
applying MSP four times per day.

We have seen excellent results using MSP therapy in Herpes genitalis. If MSP
is applied topically when itching and soreness occurs prior to vesicular
eruption it prevents eruption in more than 50% of the cases. Eruptions are
mild when they do occur. If treatment is continued b.i.d. topically to the
area, the infection clears in half the usual time. Patient should also take
2 teaspoons of MSP orally daily and remain on 1 teaspoon per day to help
eliminate future out-breaks.

Herpes Zoster(shingles) has been successfully treated as well. Pain is
substantially relieved and duration of eruption reduced as indicated above
with h. genitalis, (same Protocol).

Mild Silver Protein is not a standard colloidal silver suspension. It is
made by a licensed laboratory, that has research to substantiate its
efficacy and safety for use in vivo to control infection.*

Many companies have jumped on the bandwagon producing colloidal silver
products. Many are unstable; rendering them useless. Most are formulated
with only 3 to 6 ppm. Silver suspensions are not homeopathic remedies. They
are more effective in higher concentrations. The lab formulates MSP at 30
ppm and 40 ppm as a dietary supplement, and topical application. These are
the types of concentrations I use in my practice, and they are responsible
for the results achieved with patients coming to my clinic that I have
shared with you in this article.*
Booklet Page #10
If you and your doctor had access to something that would effectively kill
all kinds of infections, and that was completely non-toxic with no side
effects, it would be a blessing.

Mild Silver Protein has proven to be that blessing in my practice.
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #11

Personal Experience with Lyme Disease and Candida

by Dr. Paul Farber

In July of 1992 I was bitten by the Deer Tick (Ixodes Scapularis) which
according to Dr. Thomas Craig, D.V.M. of the Department of Veterinary
Microbiology and parasitology carries the Spirochete which is the causative
agent of Lyme disease. After my diagnosis was confirmed a medical doctor,
who is a neurologist, put me first on Penicillin orally for two weeks, and
then intravenously for four weeks. The results to my symptomatology were
minimal and I experienced many side effects including Candida Yeast
Infection because of the penicillin's destructive effect on the friendly
acidophilus bacteria in my stomach and colon. Since this treatment did not
work, the neurologist prescribed a cephalosporin called Rocephan.
Unfortunately, this treatment accomplished no more than the penicillin, had
many unpleasant side effects, and worsened my candida yeast infection.

Not knowing what to do, or where to go next I was led to a Dr. Joseph Cardot
from Colorado. He told me that Mild Silver Protein was helpful against
spirochetes and suggested a regiment to follow. I began with two tablespoons
a day for the first month holding it under the tongue sublingually for a
minute, swishing it around the mouth for ten seconds, and then gargling and
swallowing. I did the same thing for the second and third month, but only
one tablespoon per day.

By the end of the first two weeks my 35 different symptoms, including
extreme pain, paralysis, and numbness were about 25% relieved with no side
effects. By the end of the first month I was over 50% well. By the end of
the second month I was 75% well. After 3 months of treatment I was 100%
well. I have been 100% well for over 2 years. Was I cured from Lyme disease
and candida yeast infection? In my opinion and the opinion of Dr. William
Burgdorfer, Scientist Emeritus who discovered the spirochete as the
causative agent of Lyme disease, and Dr. John Parks Trowbridge, M.D. an
author and expert in the field of candida yeast infection, I appeared to be
CURED.

Dr. Burgdorfer, who became a close friend, then shared with me that the
world would not believe my results without scientific documentation.

It seems that there is enough testing from universities, and reports from
practitioners that the Mild Silver Protein developed not only works on Lyme
disease but a good deal more bacterial, viral and fungal infections.*
Go to the Lyme Disease information page.
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #12

From "Penicillin to "Mild Silver Protein"

An Answer to Lyme Disease "Without Antibiotics"
By Dr. William Burgdorfer, Ph.D.
Rocky Mountain Laboratories, Division of N.I.H.

In 1949, Dr. Sven Hellerstrsm from the Dermatalogical Clinic of Karolinska
Institute in Stockholm, Sweden presented a paper "Erythema chronicum migrans
Afzelius with meningitis" at the 43rd Annual Meeting of the Southern Medical
Association in Cincinnati, Ohio. In presenting his case, he provided
convincing evidence that both erythema and subsequent meningocerebrospinal
symptoms may develop following a tick bite. He also reported on the
successful treatment of his patient with penicillin, a drug shown previously
by his colleague Dr. Hollstrsm to be effective in the treatment of Erythema
chronicum migrans (ECM).

In the United States, ECM was first reported in 1970 on a physician bitten
by a tick while grouse hunting in northeastern Wisconsin. The attending
physician, Dr. Rudolf Scrimenti, recognized the similarity of the patient's
skin reaction to the lesions of European ECM and promptly and successfully
treated the patient with penicillin. The treatment of three additional
patients with penicillin and of one with erythromycin resulted in complete
resolution of symptoms within 48 to 72 hours.

Considered unrelated to ECM were skin lesions in 13 of 51 residents in the
eastern Connecticut towns of Lyme, Old Lyme, and East Haddam where, since
1972, clusters of inhabitants had been suffering of an illness characterized
by recurrent attacks of asymmetric swelling and pain in large joints,
especially the knee. Since such arthritic conditions were not known to be
associated with ECM in Europe, the illness was thought to be a new clinical
entity and was named Lyme arthritis, later changed to Lyme disease once it
was realized thatarthritis was only one of several clinical manifestations
of this disease.

The search for effective antibiotics in the treatment of Lyme disease began
in 1982 with my discovery of a spirochete now known as Borrelia burgdorferi
as the causative agent of Lyme disease and of ECM and related disorders
(acrodermatitis chronica atrophicans, lymphadenosis benigna cutis) in
Europe. The antibiotics found effective include tetracyclines (doxycycline,
minocycline), penicillins (penicillin G, amoxycillin), cephalosporins
(cefataxim, ceftriaxone), and erythromycin. Application of these drugs
depends on the time the disease is being diagnosed. Early Lyme disease is
treated orally whereas late Lyme disease requires parenteral or a
combination of parenteral and oral applications. Treatment failures have
been reported for each of these drugs particularly for the tetracyclines
that are only temporarily effective unless they are applied over long
periods of time, i.e. months even years.
Booklet Page #13
Controversy exists over the length of treatment using Mild Silver Protein
(MSP). Some investigators consider 21 to 30 days sufficient for the
elimination of the spirochetes, while others believe that patients must be
on therapy until they are completely free of symptoms.*

The diagnosis of Lyme disease is a clinical one and is based on the
development and recognition of the skin lesion (erythema migrans) a few
days, weeks, or even months, after the bite of an infected tick.
Unfortunately in up to 40% of the patients, the skin lesion does not
develop, is not recognized, or is overlooked. Thus, without treatment, the
disease spreads throughout the body and may affect the muscular, skeleton,
cardiac and nervous systems.

Indeed, Dr. Farber's recent claim having used MSP to successfully cure
himself from late stage Lyme disease, comes at a time when thousands of
patients suffering of this disease are refused extended antibiotic treatment
because their physicians are unable to associate their clinical
manifestations with those of Lyme disease.

Although never established scientifically, it appears that the Mild Silver
Protein silver colloid disables the enzyme(s) used by bacterial, fungal and
viral agents for their oxygen metabolism causing them to suffocate upon
contact. In vitro studies with Mild Silver Protein and the Lyme disease
spirochete, B. burgdorferi, revealed a 100% killing effect within less than
five minutes after exposure to the silver preparation.*
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #14

TRIAL RESULTS OF
MILD SILVER PROTEIN
IN LYME DISEASE*

Preliminary laboratory studies on Borrelia burgdorferi spirochetes revealed
that mild silver protein solutions reduce the growth rate of these cells
significantly and eventually lead to cell death. It has been pointed out,
however, that the spirochetes tested belong to a laboratory ATCC strain
which is widely used in cell and tissue cultures and does not represent
recent isolates from Lyme disease patients. In these tests, various
concentrations of silver protein solutions were added to the culture of
Borrellia spirochetes. Low concentrations of a silver protein solution
(ranging from 2 to 10 parts per million) slowed the growth rate of the
spirochetes over a time span of 1 to 3 days. Higher concentrations of silver
protein (between 15 to 75 parts per million) had a much faster deleterious
effect on cell replication. Growth inhibition depended on the concentration
of the silver protein and on the duration of treatment.

More studies are definitely necessary to obtain a clearer picture of the
interaction between the silver protein and Borrelia burgdorferi. As these
very preliminary studies suggest, growth and replication of Lyme spirochetes
are measurably inhibited by silver protein in the in vitro setting.

Manfred E. Bayer, M.D.
Senior Member
Fox Chase Cancer Center, Institute for Cancer Research
Philadelphia, PA 19111

Margret H. Bayer, Ph.D.
Senior Research Associate
Fox Chase Cancer Center, Institute for Cancer Research
Philadelphia, PA 19111

[Image]
Return to Table of Contents
------------------------------------------------------------------------
Booklet Page #15
DEPARTMENT OF HEALTH & HUMAN SERVICES

[Image]Public Health Service

National Institutes of Health
Rocky Mountain Laboratories
Hamilton, Montana 59840
(406) 363-3211
FTS (700) 322-8400

January 13, 1995

Dear Sir:*

This is to inform you that we have received a sample (12 ml) of your
colloidal silver (1,500 ppm) preparation and have evaluated its
effectiveness in a preliminary pilot study against Lyme disease spirochete,
Borrelia burgdorferi (B31) and against the relapsing fever agent, B. Hermsii
(HS-1).*

In both tests, BSK cultured spirochetes were treated with 150 and 15 ppm of
colloidal silver. When examined 24 hours later, none of the treated cultures
contained live spirochetes. Few spirochetes, all dead, were observed at 48
hours.

Additional in vitro and in vivo studies are in progress and will be reported
as soon as results become available.

Sincerely yours,
[Image]
Willy Burgdorfer, Ph.D.
Scientist Emeritus
Rocky Mountain Laboratories

Microscopy Branch
Tom G. Schwan, Ph.D.
[Image]
Senior Staff Fellow
Laboratory of Microbial Structure and Function

WB/TGS:bk

[Image]

Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #16

Lyme Disease & HIV

The following protocol has been effective in the treatment of both Lyme
Disease and HIV.

LYME DISEASE: This protocol has been extremely effective in treating Lyme
Disease, to the extent that people afflicted with the disease becoming
asymptomatic. The largest problem stemming from this treatment appears to be
the reluctance of the individual to continue with the protocol when the
Herxheimer reaction occurs. The Herxheimer reaction occurs in 80% of the
cases when candida is present, and can vary in degree of severity on a case
by case basis. Candida is present in almost all Lyme cases due to prolonged
antibiotic usage. To estimate the severity of the reaction one must assess
the progression or extent of candida. The Herxheimer reaction does not
appear to be as severe if very small amounts are used for 7 days prior to
beginning the full protocol amount.

The treatment period seems to vary from individual to individual.
Substantial improvement is noted in most cases after two weeks on the full
protocol. Within thirty days dramatic improvement is noticed in most cases.
Continuing treatment for six months usually results in the individual being
asymptomatic. Ongoing testing and trials may well prove that one injection
of *this concentrated MSP may cure the disease.
Booklet Page #17
HIV: This protocol has been shown to be very effective in staving off HIV
related infections while treating potentially dangerous related viral,
bacterial, and fungal infections in the process. It has been reported to us
that life threatening HIV related afflictions have been rectified using this
protocol, including untreatable skin lesions which lead to life threatening
infections, and beginning or mild cases of Kaposi's Sarcoma. We have not
reviewed any clinical testing that would show MSP could treat or kill cancer
cells. Nor in our inquiries have we found that any testing has ever been
done with MSP regarding any forms of cancer. We have found in past
literature that silver ions kill cancer cells, however, silver ions can be
extremely toxic if not controlled. The controlling and localizing of these
ions could well be an answer to manycancers in the future.

Since no cancer cell testing has been conducted, it is unknown if MSP has
any effect on cancer, although it has been hypothesized that once MSP
attacks the bacterial, viral, and fungal infections the immune system itself
could address theKaposi's Sarcoma with the help of immune system stimulants,
such as those found in the protocol.

It is doubtful that the protocol stated would have much effect on patients
with AIDS that have a T-cell count below 100, and who are presently affected
by a life threatening affliction.

The developer and manufacturer of MSP, believes that HIV can be treated and
cured through the use of high concentrations of MSP injected directly into
the blood, and with the use of certain immune stimulants as an adjunct.

The manufacturer states that plans are underway to have this testing
conducted outside the U.S. due to the constant federal and state
intervention which has delayed the development of this product, and others,
over the past three years.
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #19

Infection

Anyone who has an infection should avoid:
Milk Products & Citrus Fruit and Juice
Milk products provide a medium for bacterial growth which can worsen your
condition. Citrus alkalizes your system which also permits easier bacterial
growth.

Avoid Milk Products Avoid Citrus

Cheese[Image] Oranges[Image]
Icecream[Image] Pineapple[Image]
Milk[Image] Tangerine and Kiwi[Image]
Butter[Image] Citrus Juice[Image]
Yogurt[Image] Lime and Lemon[Image]
Gravies and Pudding[Image] Grapefruit[Image]

Note: Pineapple and Kiwi are not citrus fruits, but they affect you in the
same way.
Lactose Maldigestion - Milk Allergy - Casein Intolerance
http://www.panix.com/~nomilk/
Chrohn's Disease and Milk http://www.panix.com/~nomilk/crohns.shtml
Return to Table of Contents
------------------------------------------------------------------------
Booklet Page #20
[Image]
TEMPLE UNIVERSITY
A Commonwealth University

School of Medicine
Department of Microbiology and Immunology

Philadelphia, Pennsylvania 19140
(215) 707-3203
Fax: (215) 707-7788

March 20, 1995

Dear Sir:*

My laboratory has studied the effects of Special Formulation of Mild Silver
Protein on human immunodeficiency virus type 1 (HIV-1) survival and on
latency reactivation of HIV-1 in the human lymphoblastoid B cell line,
M57-3. The results of our preliminary experiments are presented in the two
tables below. Table 1 shows the viricidal properties of Special Formulation
of Mild Silver Protein while Table 2 shows the ability of Special
Formulation of Mild Silver Protein to inhibit reactivation of HIV-1 from
M57-3.

Table 1 In vitro viricidal properties of Special Formulation of Mild Silver
Protein on HIV-1 III b strain after one hour treatment with Special
Formulation of Mild Silver Protein at 37¡C as measured by syncytia formation
on SupT1 cells.
Booklet Page #21

Concentration of Special Formulation of Dilution of HIV-1 which induced
Mild Silver Protein in parts per million Syncytia Formulation on SupT1 cells
(ppm)
10-1 10-2 10-3 10-4
1000.0 ppm 0 0 0 0
100.0 ppm + 0 0 0
10.0 ppm + 0 0 0
1.0 ppm ++ ++ + +
0.1 ppm +++ +++ ++ +
None +++ +++ ++ +

The results the above experiment show that exposure of HIV-1 to 1000 ppm of
Special Formulation of Mild Silver Protein for one hour at 37¡C completely
eliminates infectious HIV-1 as measured by syncytia formation on SupT 1
cells. Exposure to between 100 ppm and 10ppm for one hour at 37¡C
significantly reduces HIV-1 infectivity as measured by syncytia formation on
SupT1 cells.

Table 2 In vitro effect of Special Formulation of Mild Silver Protein on
Recovery of HIV-1 from latently infected Lymphoblastoid B cell line M57-3.

Concentration of Special Formulation Number of Lymphoblastoid Cells
required
Mild Silver Protein in parts per million to induce Syncytia Formation when
cocultured
(ppm) with SupT1 cells

10-1 10-2 10-3 10-4
1000.0 ppm 0 0 0 0
100.0 ppm 0 0 0 0
10.0 ppm 0 0 0 0
1.0 ppm ++ ++ + +
0.1 ppm +++ +++ ++ +
None +++ +++ ++ +

These experiments above show that exposure of Human Lymphoblastoid cells
latently infected with HIV-1 strain IIIB to special formulation of mild
silver protein at 1000 and 100 ppm eliminates latently infected HIV-1 as
measured by the ability of the Lymphoblastoid cell to form syncytia when
cocultured with SupT1 cells. Exposure of Lymphoblastoid cells to 10ppm of
special formulation of Mild Silver protein significantly reduces their
ability to form syncytia when cocultured with SupT1 cells.

Taken together these new in vitro results on the viricidal (anti-HIV-1)
properties of Special Formulation of Mild Silver Protein and the ability of
Special Formulation of Mild Silver Protein to inhibit latency reactivation
in a human lymphoblastoid cell together with our previous results on
inhibition of HIV-1 replication in vitro demonstrate some of at the invitro
bioactive properties of Special Formulation of Mild Silver Protein. A
possible future avenue of research could be to determine whether Special
Formulation of Mild Silver Protein has synergistic or additive effects
against HIV-1 in vitro when combined with approved therapeutic AIDS drugs
such as Azido deoxythymidine (AZT) or Interleukin-2 (IL-2)

Sincerely,
[Image]
Earl E. Henderson, Ph.D.
Professor
Return to Table of Contents
------------------------------------------------------------------------
Booklet Page #22
Susan Buck
1403 E. Sunset Dr. #11

August 15, 1995

To the developer and manufacturer of Mild Silver Protein*

RE: Personal testimony / Mild Silver Protein

Dear Sir:*

In the late 1980's I was diagnosed as being manic depressive. In 1992 I was
tested HIV+. For depression I was given trazadon, but because of side
effects I quit taking medication, and in doing so I was caught up in the
roller coaster ride of manic depression. For years and years of my life I
knew no calm or rest mentally, and then of course physically I was off
center too! Then in 1992 when I tested HIV+ this triggered the worst
episodes of my life with depression. Also, when the weather was rainy and
cloudy as it often is in Washington, my depression would usually worsen,
meaning I would suffer with a deeper, darker sense of depression. Not that
these episodes were more frequent, but they seemed deeper, and darker.

As stated before concerning my HIV+ condition, I tested positive for the
virus in February of 1992. As time goes on so do the numerous ill effects
that the HIV virus wreaks upon the human body. Some of the conditions I have
dealt with are as follows: Night sweats, swollen and inflamed glands,
extreme fatigue, poor digestion, lack of mental concentration, muscle
weakness, poor circulation and severe candida. Also, due to TMJ and jaw
surgery and thousands of dollars worth of orthodontics and dental care, I
have developed sinus problems. I would rise in the morning with extremely
painful headaches that would last all day.

On the subject of Candida, I had it both orally and vaginally. By observing
the protocol and taking Mild Silver Protein as instructed, not only has my
candida subsided, but all other health related issues due to the HIV virus
have disappeared. Mild Silver Protein has significantly reduced the number
and severity of my bouts with depression. In the month I have been using
Mild Silver Protein I have had one attack with depression, and I suspect the
reason for that one was hormonal (I changed estrogen replacement pills).
Before, it wasn't unusual for me to spend two to three weeks out of a month
in a depressed state of being.

I tried chiropractic treatment and had adjustments for almost seven months
before I decided that not only were the treatments expensive every month,
but these adjustments did not help alleviate the frequency of the headaches.
I decided to put a few drops of Mild Silver Protein in both sides of my
nasal cavity, and within a few seconds the solution had penetrated into the
sinuses and had absolutely done away with the typical and usual headaches I
woke with. I do this treatment every morning I need to, which is
approximately two to three times a week. As a result, myheadaches have been
far less frequent and less painful during the 30 days I have been using Mild
Silver Protein. This week I have had only one headache, and don't expect any
more.
Booklet Page #23
Regarding my husband's use of Mild Silver Protein: He has had a massive cyst
on his rib cage for six years. It has grown larger every year since its
discovery. My husband started very Mild Silver Protein the same time I did.
Within two weeks of his starting to use Silver Protein, we discovered, much
to our surprise and delight, that the size and length of the mass had shrunk
by over 50%. It is now half its previous size, and less tender to the touch.
In addition, my husband has also had success with Mild Silver Protein
concerning the number and severity of his problems withathlete's foot.

I would like to thank and commend you, your staff and your company for
developing and producing the product Mild Silver Protein. I have had
wonderful successes with this product, with absolutely no ill side effects
from either the Mild Silver Protein or the protocol supplements. I suspect I
may never rid myself of the gene which causes my depression or rid myself of
the HIV virus. But it is the quality of my life that is of importance to me,
and your product, Mild Silver Protein, is responsible for all the joy of
good health which I am currently enjoying.

In closing, thank you for enabling me to live a life, a life I never knew
existed before. I have no plans for ever discontinuing the use of Mild
Silver Protein or its protocol.

Gratefully,
[Image]
Susan Buck
Return to Table of Contents
------------------------------------------------------------------------
Booklet Page #24
[Image]
TEMPLE UNIVERSITY
A Commonwealth University

School of Medicine
Department of Microbiology and Immunology

Philadelphia, Pennsylvania 19140
(215) 707-3203
Fax: (215) 707-7788

July 18, 1995

The Manufacturer of Mild Silver Protein

Dear Sir:*

My laboratory has studied the effects of Silver Solution (pure silver
suspended in water at 150 ppm), Mild Silver Protein (Nitrate and Nitrite
Free at 1250 ppm) and Mild Silver Protein (30 ppm in H2O) on human
immunodeficiency virus type I (HIV-1) replication and syncytic formation in
culture. The results of our preliminary experiments are presented in the
table below.

Table 3 In vitro viricidal properties of Silver Solution, Mild Silver
Protein (Nitrite and Nitrite Free) and Mild Silver Protein (Dietary
Supplement) on HIV-1 III § strain replication in Supt1 cells as measured by
syncytia formation.

Formulation of Silver Dilution of HIV-1 which Inducted
Syncytia Formation

Silver Solution
Concentration 10-1 10-2 10-3 10-4

15.00 ppm + 0 0 0
1.50 ppm +++ ++ + +
0.15 ppm +++ +++ ++ +
None +++ +++ ++ +

Mild Silver Protein
(Nitrate & Nitrite Free) 10-1 10-2 10-3 10-4

125.000 ppm 0 0 0 0
12.500 ppm ++ +- 0 0
1.250 ppm +++ ++ + 0
0.125 ppm +++ +++ ++ 1
None +++ +++ ++ 1

Booklet Page #25

*
Mild Silver Protein 10-1 10-2 10-3 10-4

3.00 ppm + + 0 0
0.30 ppm ++ ++ + +
0.03 ppm +++ +++ ++ +
None +++ +++ ++ +

AZT (10 mm) 0 0 0 0

Taken** as a whole these experiments show an in vitro effect with Mild
Silver Protein (Nitrate and Nitrite Free) as well as * on HIV replication in
the human T cell line, Supt 1. This inhibition of HIV-1. Replication is
dependent on the concentration of Mild Silver Protein. I trust these
preliminary in vitro results using very low concentrations of Mild Silver
Protein will interest you.

Sincerely,
[Image]
Earl E. Henderson, Ph.D.
Professor of Microbiology
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #26

Toxicity of Mild Silver Protein, Jan 27, 1995

Product:
Mild Silver Protein provided by manufacturer*

Testing Facility: All tests were performed under the direction of Dr. R.C.
Renlund, DVM, by staff of the Division of Comparative Medicine (DCM),
Medical Sciences Building, Faculty of Medicine, University of Toronto.
All experimental procedures were performed according to ethical guidelines,
approved by the appropriate committee on animal experimentation.

This report is a summary of reports prepared by Dr. R.C. Renlund.

Summary: The aim of this study was to examine the health effects in rats
exposed to either acute or chronic administration of Mild Silver Protein
solutions at various concentrations either by intravenous injection or by
presentation in drinking water. An initial (dose finding) study where rats
received injections, via tail vein, of either 0.015, 0,075 or 0.15 mg in 1
ml of physiological saline solution, showed no observable ill effects either
immediately or 8 days after injection. In a follow up study, 4 rats in each
of 2 groups that had received intravenously, daily either 0.015 or 0.15 mg
Mild Silver Protein in 1 ml of physiological saline after 12 days of
treatment showed no abnormal, clinical or behavioral signs. In a further
follow up study, applying high dose injections of 1500 ppm Mild Silver
Protein to 3 animals, 3 times per week for 4 weeks no clinical signs or
gross pathological changes were observed. The weight gain of the treated and
3 control animals showed no significant difference. Alternatively, 15 rats
fed with Mild Silver Protein solution in their drinking water, 1.5 ppm for
40 days, which 18 mg total/350 gram rat, also showed no clinical signs of
gross pathological changes at the end of the 40 day period.
Booklet Page #27
Protein stabilized mild silver solutions are said to possess antiseptic
properties. These solutions seem to provide means of controlling infections
which may not be responsive to currently available antibiotics. If these
preparations are to be applied in vivo, it is necessary first to obtain
measures of tolerance or toxic reactions. The following studies profile the
toxic response in the rat model were performed.

Materials, animals and methods: The material tested was a specially
formulated protein-stabilized silver solution called Mild Silver Protein. It
was supplied by the manufacturer.* Standard Wistar rats were obtained from
Harlan Sprague Dawley, housed in plastic cages with automatic watering
system and were fed Ralston Purina Lab Chow 5001. To obtain a sensitivity or
a toxicity profile, using a minimal number of animals, a staged experimental
approach was used. Dose finding experiments were either injected via tail
vein or exposed by addition of the silver preparation in the drinking water.
The animals were weighed daily and examined for gross pathological features.

Toxicity tests: The experimental conditions and results are given in the
reports from Dr. Renlund and reiterated here in brief.

Test 1: (DCM report, 26, July 1994)
Ten rats ranging in weight 176 - 200 grams were divided into 3 treatment
groups, A, B, and C, with 3 animals each and one served as an optional
control. A single dose, 1 ml of 0.15, 0.075 and 0.015 mg/ml Mild Silver
Protein Solution was administered using the tail vein.

The animals were observed for an 8 day period and neither clinical nor
behavioral signs were seen.

Test 2: (DCM report, September 2, 1994)
Ten rats ranging in weight 176 - 200 grams were obtained from the supplier
noted above and divided into groups A, B, and C with 4, 4 and 2 animals in
those groups. Individuals were marked and received 1 ml of 0.15, 0.015 mg/ml
Mild Silver Protein in group A and B respectively, daily for 12 days, by
injection via tail vein. The 2 animals on the control group, C were sham
injected with 1 ml of normal physiological saline.
There were no observable clinical or behavioral signs after the 12 day
exposure period.
Booklet Page #28
Test 3: (DCM report, December 15, 1994)
Eighteen rats were divided into a treatment group comprising 15 individually
marked animals that were fed with Mild Silver Protein solution in drinking
water (1.5 ppm) over a 40 day period. Three animals were fed regular
drinking water and served as controls. All animals received normal rat chow
(see above) and were weighed daily.
After the 40 day period none of the animals showed clinical signs, abnormal
behavior or gross pathological features.

Test 4: (DCM report, January 2, 1995)
In a high dose study 6 rats were divided into 2 groups of 3 animals each,
groups A and B respectively. Animals in group A received 1 ml of 1.5 mg/ml
Mild Silver Protein solution by injection into a tail vein, 3 times a week
for 4 weeks, which is 18 mg total for rats weighing about 300 grams. The
control group B, received sham injections at the same time schedule. The
animals were weighed at regular intervals.
Over the treatment period there were no clinical signs and no gross
pathological changes associated with the chronic intravenous injections were
observed.

This report is based entirely upon the data provided by Dr. Renlund,
Director of the DCM (For details see data provided by Dr. Renlund).

N.B.: At the highest dose (18 mg / 300 gram rat) there were no observed
adverse effects within the treatment period; the data does not permit us to
make a statement regarding the metabolic fate of the silver. If these data
can be extrapolated to the human scale, then a 60 kilogram individual would
have to be given 3,600 mg (3.6 grams) to receive an amount equivalent to the
test animal (rats). This corresponds to the injection of 1 ml of a solution
containing 300,000 ppm of Mild Silver Protein.

[Image]
John Barltrop
M.A., D.Phil, D.Sc.

*44 rats = total studied
*Highest dosage injected intraveneously through tail vein is the equivalent
of a human being taking 86 4oz. bottles in one week or 12 full 4oz. bottles
every day with no side effects observed.
Based on the animal model that's a dozen bottles a day for a human without
any side effects.
Return to Table of Contents
------------------------------------------------------------------------
Booklet Page #29
August 26, 1994

To the developer and manufacturer of Mild Silver Protein*

Dear Sir:*

Enclosed are the results from the experiments I performed on your Test
Specimen on a drug-resistant clinical strain of Enterococcus obtained from
an area hospital. Unfortunately, the Test Specimen was not very effective
against Enterococcus at the concentrations tested. No inhibition was
observed by the broth dilution procedure at Test Specimen concentrations up
to 750 ppm (the highest concentration possible with the 1500 ppm Test
Specimen provided). On the direct application plate test, the Test Specimen
moderately inhibited Enterococcus at a concentration of 1500 ppm, but did
not inhibit at 300 ppm.

It is possible that higher concentrations of your Test Specimen may be
effective against this drug-resistant bacterium. Please let me know if you
wish to test higher concentrations of the Test Specimen or if you wish to
check bactericidal activity of the Test Specimen against other bacteria.

Sincerely,

*(CONFIDENTIAL - Released on a Need To Know basis)

Enclosure

Product tested: Mild Silver Protein in Colloidal Suspension.*
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #30

FINAL REPORT

TO: The manufacturer of Mild Silver Protein*

TITLE: Bactericidal Activity of Test Specimen Against Drug-Resistant
Enterococcus

DATE: August 26, 1994

Test Specimen, provided by manufacturer,* was tested for bactericidal
activity against a drug-resistant clinical strain of Enterococcus (resistant
to penicillin, vancomycin, kanamycin, polymyxin B, tetracycline, coliston,
and cefotetan) obtained from an area hospital. The following experiments
were performed to determine bactericidal activity of the Test Specimen: (1)
Direct application of Test Specimen at 1500 ppm (assumed to be undiluted
concentration of Test Specimen) and 300 ppm onto sheep blood agar plates
seeded with Enterococcus, (2) broth dilution testing of Test Specimen at 750
ppm, 375 ppm, 187.5 ppm, 93.75 ppm, and 0 ppm for bactericidal activity
against Enterococcus, and (3) broth dilution testing of filter-sterilized
Test Specimen at 750 ppm, 375 ppm, 187.5 ppm, and 93.75 ppm for bactericidal
activity against Enterococcus.

RESULTS:

(1) Direct Application of Test Specimen A

Ten microliters of filter-sterilized (0.2µm filter) and nonfilter-sterilized
Test Specimen (1500 ppm and 300 ppm, which was prepared by dilution in
sterile distilled water) were pipetted onto sheep blood agar plates seeded
with Enterococcus. The inoculated plates were incubated at 37¡C in a 5% CO2
incubator for 24 hours. After incubation, plates were examined for growth or
no growth of bacteria in the areas containing the Test Specimens. The
following results were obtained from this experiment:

Concentration Enterococcus Enterococcus
(nonfiltered Test Specimen) (filtered Test Specimen)

1500 ppm Moderate inhibition of Moderate inhibition of
Bacteria (1) Bacteria (1)

300 ppm No inhibition of bacteria No inhibition of bacteria

(1) Partial to complete zone of inhibition.
Booklet Page #31
(2) Broth Dilution Testing of Test Specimen

The broth dilution procedure, which commonly is used to determine minimal
bactericidal concentrations (MBC) of antimicrobial agents, was used to
determine the effectiveness of the Test Specimen against Enterococcus. The
Test Specimen was serially diluted in sterile Todd- Hewitt broth and
combined with Enterococcus (0.5 McFarland Standard turbidity) to final Test
Specimen concentrations of 375 ppm, 187.5 ppm, and 93.75 ppm. A control
containing 0 ppm Test Specimen was included. In addition, Test Specimen was
combined directly with Enterococcus (0.5 McFarland Standard turbidity) to
achieve a final Test Specimen concentration of 750 ppm. Broth tubes were
incubated at 37 C in a 5 % CO2 incubator for 24 hours. Following this
incubation period, broth tubes were visually examined for signs of growth
(turbidity). A loopful of each broth culture was streaked onto a sheep blood
agar plate to determine growth or no growth of bacteria. The following
results were obtained from this experiment:

Concentration Enterococcus

750.00 ppm Growth (Growth)(2)
375.00 ppm Growth (Growth)
187.50 ppm Growth (Growth)
93.75 ppm Growth (Growth)
0.00 ppm Growth (Growth)

(2) Results expressed as growth or No Growth as visually observed in broth
cultures (Growth or No Growth as determined by streaking of broth cultures
onto sheep blood agar plates). Growth results from streaking of broth
cultures onto sheep blood agar plates are more reliable than growth results
determined by visual observation.
Booklet Page #32
(3) Broth Dilution Testing of Filter-Sterilized Test Specimen

Test Specimen was filter sterilized, using a 0.2µm filter, to remove
potential contaminants. The filtration flow rate was very slow and only a
small amount of Test Specimen could be filter- sterilized. The
filter-sterilized Test Specimen was tested for bactericidal activity by the
broth dilution procedure described in the previous section. The following
results were obtained:

Concentration Enterococcus

750.00 ppm Growth (Growth)(2)
375.00 ppm Growth (Growth)
187.50 ppm Growth (Growth)
93.75 ppm Growth (Growth)

(2) Results expressed as Growth or No Growth as visually observed in broth
cultures (Growth or No Growth as determined by streaking of broth cultures
onto sheep blood agar plates). Growth results from streaking of broth
cultures onto sheep blood agar plates are more reliable than growth results
determined by visual observation.

CONCLUSIONS:

The Test Specimen did not inhibit growth of the drug-resistant Enterococcus
at concentrations up to 750 ppm when tested by the broth dilution procedure.
The Test Specimen appeared to moderately inhibit (partial to complete zone
of inhibition) Enterococcus at a concentration of 1500 ppm, but not at a
concentration of 300 ppm, during direct application on seeded sheep blood
agar plates. Similar results were obtained with filtered and unfiltered Test
Specimen.
Return to Table of Contents
------------------------------------------------------------------------
Booklet Page #33
Product Tested:
Mild Silver Protein in Colloidal Suspension*

FINAL REPORT

TO: The developer & manufacturer of Mild Silver Protein*

FROM: (CONFIDENTIAL - Released on a Need To Know basis)

RE: Bactericidal Activity of Test Specimen

DATE: May 6, 1994

Three different experiments were performed on Escherichia coli (ATCC 25922)
and Staphylococcus aureus (ATCC 25923), two bacteria commonly used in
antimicrobial susceptibility testing, to determine the bactericidal activity
of the Test Specimen: (1) Direct application of Test specimen at 1500 ppm
and 150 ppm onto sheep blood agar plates seeded with E. coli and S. aureus,
(2) broth dilution testing of Test specimen at 150 ppm, 75 ppm, 37.5 ppm,
and 0 ppm for bacterial activity against E. coli and S. aureus, and (3)
broth dilution testing of filter-sterilized Test specimen at 150 ppm, 75
ppm, and 37.5 ppm for bactericidal activity against E. coli and S. aureus.

RESULTS

The following results were obtained from these three experiments.

(1) Direct Application of Test Specimen

Ten microlitres of filter-sterilized and non filter-sterilized Test Specimen
were pipetted onto sheep blood agar plates seeded with E. coli and S.
aureus. The plates were then incubated at 37¡ C for 24 hours and examined
for growth or no growth of bacteria in the areas containing the Test
Specimen. Filter-sterilized and non filter-sterilized Test Specimen at
concentrations of 1500 ppm inhibited growth of E. coli and S. aureus;
filter-sterilized and non filter-sterilized Test Specimen at concentrations
of 150 ppm did not inhibit growth of these bacteria.

(2) Broth Dilution Testing of Test Specimen

The broth dilution procedure, which commonly is used to determine minimal
bactericidal concentrations (MBC) of antimicrobial agents, was used to
determine the effectiveness of the Test Specimen against E. coli and S.
aureus. The Test Specimen was serially diluted in sterile Trypticase soy
broth and combined with E. coli or S. aureus (0.5 McFarland Standard
turbidity) to final Test Specimen concentrations of 150 ppm, 75 ppm, and
37.5 ppm. A control containing 0 ppm Test Specimen was also included. Broth
tubes were incubated at 37¡C for 24 hours. Following this incubation period,
a loopful of each broth culture was streaked onto a sheep blood agar plate
to determine growth or no growth of bacteria. The following results were
obtained from this experiment:
Booklet Page #34
(2) Broth Dilution Testing of Test Specimen A

The broth dilution procedure, which commonly is used to determine minimal
bactericidal concentrations (MBC) of antimicrobial agents, was used to
determine the effectiveness of Test Specimen A against S. pneumoniae and P.
aeruginosa. Test Specimen A was serially diluted in sterile Todd-Hewitt
broth and combined with S. pneumoniae (0.5 McFarland Standard turbidity) or
serially diluted in sterile Trypticase soy broth and combined with P.
aeruginosa (0.5 McFarland Standard turbidity) to final Test Specimen
concentrations of 375 ppm, 187.5 ppm, and 93.75 ppm. A control containing 0
ppm Test Specimen was included. In addition, Test Specimen was combined
directly with S. pneumoniae and P. aeruginosa (0.5 McFarland Standard
turbidity) to achieve a final Test Specimen concentration of 750 ppm. Broth
tubes were incubated at 37¡C for 24 hours (for P. aerginosa) or at 37 C in a
5 % CO2 incubator for 24 hours (for S. pneumoniae). Following this
incubation period, broth tubes were visually examined for signs of growth
(turbidity). A loopful of each broth culture was streaked onto a sheep blood
agar plate to determine growth or no growth of bacteria. The following
results were obtained from this experiment:

Concentration S. pneumoniae P. aeruginosa

750.00 ppm No Growth (No Growth)* No Growth (No Growth)
375.00 ppm No Growth (No Growth) No Growth (Slight Growth)
187.50 ppm No Growth (No Growth) No Growth (Growth)
93.75 ppm No Growth (No Growth) No Growth (Growth)
0.00 ppm Growth (Growth) Growth (Growth)

*Results expressed as Growth or No Growth as visually observed in broth
cultures (Growth or No Growth as determined by streaking of broth cultures
onto sheep blood agar plates). Growth results from streaking of broth
cultures onto sheep blood agar plates are more reliable than growth results
determined by visual observation.

(3) Broth Dilution Testing of Filter-Sterilized Test Specimen A

Test Specimen A was filter sterilized, using a 0.2µm filter, to remove
potential contaminants. The filtration flow rate was very slow and only a
small amount of Test Specimen could be filter- sterilized. The
filter-sterilized Test Specimen was tested for bactericidal activity by the
broth dilution procedure described in the previous section. The following
results were obtained:
Booklet Page #35

Test Specimen Concentration E. coli S. aureus

150.0 ppm Growth Growth
75.0 ppm Growth Growth
37.5 ppm Growth Growth
0.0 ppm Growth** Growth**

(3) Broth Dilution Testing of Filter-Sterilized Test Specimen

Test specimen was filter sterilized, using a 0.2µm filter, to remove
potential contaminants. The filtration flow rate was very slow and only a
small amount (approximately 0.5 ml) of Test Specimen could be
filter-sterilized. The filter-sterilized Test Specimen was tested for
bactericidal activity by the broth dilution procedure described in the
previous section. The following results were obtained:

Test Specimen Concentration E. coli S. aureus

150.0 ppm No Growth Growth
75.0 ppm No Growth Growth
37.5 ppm Growth Growth

CONCLUSIONS:

The Test Specimen inhibited growth of E. coli and S. aureus at a
concentration of 1500 ppm, but not at 150 ppm during direct application on
seeded sheep blood agar plates. Filter-sterilized Test Specimen was
bactericidal for E. coli at a concentration of 150 ppm and 75 ppm by the
broth dilution test, but was not bactericidal for S. aureus at
concentrations up to 150 ppm. Non filter- sterilized Test Specimen was not
bactericidal for either bacteria at concentrations up to 150 ppm by the
broth dilution test. The differences in the broth dilution test results for
E. coli suggest that at concentrations of 150 ppm or lower, the Test
Specimen may give variable bactericidal results.
Return to Table of Contents

------------------------------------------------------------------------
Booklet Page #36
FINAL REPORT

TO: *(Confidential - Released on a Need To Know basis)

FROM: *(Confidential - Released on a Need To Know basis)

RE: Bactericidal Activity of Test Specimens A and B

Date: June 17, 1994

(A=INVIVE - REVIVE SILVER TYPE) Ñ (B="NOT" INVIVE - REVIVE SILVER TYPE=other
brands)

Test Specimens A (original specimen, dark colored) and B (olive green
colored) were tested for bactericidal activity against a clinical strain of
Streptococcus pneumoniae (resistant to penicillin) and a clinical strain of
Pseudomonas aeruginosa (resistant to ampicillin, tetracycline,
trimethyoprim, cefazolin, cefoxitin, cefuroxime, and cephalothin) obtained
from an area hospital.

The following experiments were performed to determine bactericidal activity
of Test Specimen

A: (1) Direct application of Test Specimen A at 1500 ppm (assumed to be
undiluted concentration of Test Specimen) and 300 ppm onto sheep blood agar
plates seeded with S. pneumoniae and P. aeriginosa, (2) broth dilution
testing of Test Specimen A at 750 ppm, 375 ppm, 187.5 ppm, 93.75 ppm, and 0
ppm for bactericidal activity against S. pneumoniae and P. aeruginosa, and
(3) broth dilution testing of filter-sterilized Test Specimen A at 750 ppm,
375 ppm, 187.5 ppm, and 93.75 ppm for bactericidal activity against S.
pneumoniae and P. aeruginosa. The following experiment was performed to
determine bactericidal activity of Test Specimen B:

Direct application of Test Specimen B at 1500 ppm (assumed to be undiluted
concentration of Test Specimen) and 300 ppm onto sheep blood agar plates
seeded with S. aereus (ATCC 25923).

RESULTS

EXPERIMENTS WITH TEST SPECIMEN A:

(1) Direct Application of Test Specimen A

Ten micro liters of Test Specimen A (1500 ppm and 300 ppm, which was
prepared by dilution in sterile distilled water) were pipetted onto sheep
blood agar plates seeded with S. pneumoniae and P. aeruginosa. The
inoculated S. pneumoniae plates were incubated at 37 C in a 5% CO2 incubator
for 24 hours. The inoculated P. aeruginos plates were incubated at 37 C for
24 hours. After incubation, plates were examined for growth or no growth of
bacteria in the areas containing the Test Specimens. The following results
were obtained from this experiment:
Booklet Page #37
*INVIVE - REVIVE SILVER TYPE

Concentration S. pneumoniae P. aeruginosa

1500 ppm Inhibition of Bacteria Inhibition of Bacteria

300 ppm Inhibition of Bacteria Inhibition of Bacteria

750 ppm No Growth (No Growth)? No Growth (No Growth)

375 ppm No Growth (No Growth) No Growth (No Growth)

187.5 ppm No Growth (No Growth) No Growth (Growth)

93.75 ppm No Growth (No Growth) No Growth (Growth)

?Results expressed as Growth or No Growth as visually observed in broth
cultures (Growth or No Growth as determined by streaking of broth cultures
onto sheep blood agar plates). Growth results from streaking of broth
cultures onto sheep blood agar plates are more reliable than growth results
determined by visual observation.

EXPERIMENT WITH TEST SPECIMEN B: (Test Silver Solution - NOT Mild Silver
Protein)

Ten microliters of Test Specimen B (1500 ppm and 300 ppm, which was prepared
by dilution in sterile distilled water) were pipetted onto sheep blood agar
plates seeded with S. aureus (ATCC 25923). The procedure was repeated with
ten microliters of Test Specimen B (1500 ppm) filter- sterilized through a
0.2 µm filter. Test Specimen B easily passed through this filter. The
inoculated S. aureus plates were incubated at 37 C for 24 hours. After
incubation, plates were examined for growth or no growth of bacteria in the
areas containing the Test Specimen. The following results were obtained from
this experiment:

("NOT" INVIVE - REVIVE SILVER TYPE = other brands)

Concentration S. aureus S. aureus

(exposed to non-filtered Test Specimen) (exposed to filtered Test Specimen)

1500 ppm No Inhibition of Bacteria No Inhibition of Bacteria

300 ppm No Inhibition of Bacteria Not Done

CONCLUSIONS:

(A=INVIVE - REVIVE SILVER TYPE) Ñ (B=other brands )

Test Specimen A inhibited growth of S. pneumoniae at concentrations of 1500
ppm and 300 ppm during direct application on seeded sheep blood agar plates
and at concentrations of 93.75 ppm, 187.5 ppm, 375 ppm, and 750 ppm by the
broth dilution test. Test Specimen A inhibited growth of P. aeruginosa at
concentrations of 1500 ppm and 300 ppm during direct application on seeded
sheep blood agar plates and at concentrations of 375 ppm (only partial
inhibition with non-filtered Test Specimen at this concentration) and 750
ppm by the broth dilution test. Test Specimen B did not inhibit growth of S.
aereus at concentrations of 1500 ppm and 300 ppm during direct application
on seeded sheep blood agar plates.

------------------------------------------------------------------------
Booklet Page #38
[Image]
TEMPLE UNIVERSITY
A Commonwealth University

School of Medicine
Department of Microbiology and Immunology

Philadelphia, Pennsylvania 19140
(215) 707-3203
Fax: (215) 707-7788

February 2, 1995



Preliminary studies on your silver preparation (1500 ppm) show it to be
effective in inhibiting and killing strains of Candida albicans and
Cryptococcus neoformans in-vitro.

Four strains of C. Neoformans were tested and they were killed by the
preparation at 150-300 ppm. The growth of these strains were inhibited at a
concentration as low as 0.3 ppm.

Three strains of C. Albicans were tested and they were killed by the
preparation at between 46 and 93 ppm. Growth was inhibited at between 0.7
and 1.4 ppm.

Additional studies should be done to evaluate in-vivo effectively.

Sincerely,
[Image]
Helen R. Buckley, Ph.D.
Professor

HRB/mm
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #40

GLOBAL HEALTH INFORMATION & MEDICAL RESEARCH INSTITUTE
(GHI/MRI)

MEDICAL REVIEW BOARD MEMBERS

Barltrop, John-
M.A. D. Phil., D. Sc.
Lecturer in chemistry at Oxford, England, 35 years
co-authored two books
120 scientific journal publications.

Dean, Ward-
M.D.
Author of the following books:
Biological Aging Measurement, - Clinical Applications
Neuroendocrine Theory of Aging and Degenerative Disease
Smart Drugs & Nutrients
Smart Drugs II - The Next Generation.
Served on Board of Directors:
American Aging Society
Florida Geriatrics.

Khalsa, Dharma Singh
M.D.
President and Medical Director- Alzheimer's Prevention Foundation
Served on Board of Directors
Living Through Cancer, Inc.
American Academy of Medical Acupuncture
American Academy of Anti Aging Medicine
The Super Health Ranch
Speaker at over 60 conferences
Many publications- too numerous to mention.

Kleinsek, Don A.
Ph. D.
Genetic Scientist
President, GeriGene Medical Corporation
Served as Associate Scientist- Institute on Aging and Adult Life
Scientific Director- Bjsrksten Research Foundation
Board of Directors- American Aging Association
24 scientific publications
Owner of three patents.
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #41

GLOBAL HEALTH INFORMATION & MEDICAL RESEARCH INSTITUTE
(GHI/MRI)

(A Non-Profit Organization)
Purposes of Corporation as Specified In Article of Incorporation

1. To gather medical information on a world wide basis, and provide to the
public the knowledge of current products, practices, medical devices,
and protocols that have shown to be effective in treating medical
afflictions with an emphasis on terminal illness, quality of life and
anti-aging.
2. To gather medical information on a world wide basis, and provide to the
public the knowledge of products, practices, and protocols that are
most effective in the prevention of medical afflictions with an
emphasis placed on quality of life and terminal disease.
3. To provide money via research grants and foundation support to
individuals and organizations conducting scientific studies relating to
disease prevention and cure, and ant-aging medicine.

TO CONTINUE TO SERVE THE PUBLIC
(DONATIONS ARE NEEDED)

All donations go directly for the purposes of the corporation, some of which
are listed above. GHI/MRI has never paid employees, doctors, scientists,
universities, practitioners, board members, officers, or office staff, all
donate their time and efforts for no remuneration, October 1995.
YOUR DONATION CAN HELP SAVE SOME LIVES VIA RESEARCH AND THE PUBLIC BEING
INFORMED PROPERLY.
Make cheque or money order out to GHI/MRI in care of the distributors above.
ALL DONATIONS ARE TAX DEDUCTIBLE IN THE U.S.
Return to Table of Contents
------------------------------------------------------------------------

Booklet Page #42

REFERENCES

Barltrop, Dr. John- M.A., D. Phil., D.Sc
Burgdorfer, Dr.W.- Ph.D., Scientist Emeritus, Discoverer of Lyme Disease-
for whom Lyme Spirochete was named: Borrelia Burgdorferi
from Colorado, Dr. Joseph Cardot- M.D.
Farber, Dr. M.P.- B.A., B.S., M.A., N.D., Ph.D., D.C.
Fox Chase Cancer Center
Galbraith Laboratories
Henderson Laboratories
INTERNET Raintree Group
National Dispensatory 1927
Rocky Mountain Laboratories, Division of N.I.H.
Temple University
University of South Florida
Developer and Manufacturer of Mild Silver Protein
------------------------------------------------------------------------

Booklet Page #43

DISTRIBUTORS OF MILD SILVER PROTEIN

Throughout the United States:
APM Shipping Company
Terminal Warehouse:

Chandler, Arizona, U.S.A. 85224
TO PLACE AN ORDER: Do not send order to terminal,
Tel: 1 800 877-5097
and mail request to: International 1825 Main Street Winnipeg, Manitoba,
Canada R2V 2A4
or email: invive@invive.com
[Image]

"Limited Time "Special":
INTRODUCTORY OFFER
Lowest MSP Price on Internet
Throughout the United States:

International Pharmaceuticals
1825 Main Street
Winnipeg, Manitoba, Canada R2V 2A4
Product name: REVIVE
Distributed to Practitioners and the public
Throughout Canada:
Advantage Pharmaceuticals
1825-A Main Street
Winnipeg, Manitoba, Canada R2V 2A4
To place an order:
Tel: 1 204 694-8722 or 1 800 877-5097
or email: invive@invive.com
Product name: INVIVE
Distributed to Practitioners and the public

Starfish
= Why we distribute our "enhanced" 5,000 p.p.m. formula "to the people" even
in the face of Financial Loss,
Assault from the FDA, Promoters, and Multinational Supplement Companies:

As the old man walked down a Spanish beach at dawn, he saw ahead of him what
he thought to be a dancer. The young man was running across the sand,
rhythmically bending down to pick up a stranded starfish and throw it far
into the sea. The old man gazed in wonder as the young soul again and again
threw the small starfish from the sand into the water. The old man
approached him and asked why he spent so much energy doing what seemed a
waste of time. The young man explained that the stranded starfish would die
if left until the morning sun.

"But there are thousands of miles of beach, and miles and miles of starfish.
How can your effort make any difference?" The young man looked down at the
small starfish in his hand, and as he threw it to safety in the sea, said,
"It makes a difference to this one!"
(anonymous)
Return to Table of Contents
------------------------------------------------------------------------

Please note:
These research papers have been compiled in the interests of the public good
and well-being as a public service. This knowledge is being made available
to help those individuals searching for a truth who have been exposed to the
undocumented hearsay of uninformed misguided self-appointed experts on
silver solutions. To counter these self-appointed experts, the foregoing
hard factual data has been supplied for all to see the truth.

Further problems come with proponents of "weak" silver solutions. To them
the data shows that Bacteria can actually be grown in 3 - 5 ppm silver
solutions and it is absurd that some individuals would attempt to knock out
disease organisms with such weak and unstable silver solutions.

These are the only "new" bona fide test results on silver in all North
America for the years 1992 to 1995 that the publisher is aware of and are
provided in the interests of our country's wellness and to stop the
prevarications of some individuals.

As this is a public service effort only to promote awareness: PLEASE do NOT
call - ie: You are NOT to call the Universities or Laboratories or other
parties in this publication who have already donated more than their fair
share of time and are not to be overburdened now or inundated with calls.

The astounding test results speak for themselves and they cannot have 280
million people calling on these dedicated professionals. It is just not
feasible.

Certain city, state, and phone numbers had to be removed to prevent them
from being inundated with calls for various reasons affecting overall
well-being of themselves and other participants.

It is suffice to state that the data is strong enough to stand on it's own
merit and all procedures were conducted under the strictest laboratory
controls and the validity of the results are already attested to by the
references duly noted throughout.

Publishing Assistant

If you want further proof, the only further proof that can be is:
ps: Try this only "uniquely" formulated and stabilized 1990's Mild Silver
Protein solution which has the smallest particle size in all North America
infused into a protein molecule, and not the 1890's silver solutions, and
prove the remarkable effects and results for yourself.

pps: a fifty percent decrease in particle size results in 8 times more
particles to work for you.

The only solution that is stable in all North America;
smallest particles.
more of them.
uniquely infused into a protein molecule all resulting in enhanced
antibacterial properties.

* Names of individuals and companies withheld, document edited, at the
request of distributor. Full references available upon request.
** (sic) Spelling corrections from original documents.
*** All italicized notations and boldface provided by publisher's assistant
to enable Doctors to speed-read data.
Return to Table of Contents
January 29, 1998